Peptide Library

Human study PLS-00079

Serum MOTS-c levels remain unchanged in patients with preeclampsia.

Case-control study · 90 participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Serum MOTS-c levels remain unchanged in patients with preeclampsia.primary · Ginekologia polska · 2023-01-01 · PMID 39469962 · DOI

Design and participants

Design
Case-control study
Population
Pregnant patients: 30 with uncomplicated pregnancy, 30 with mild preeclampsia and 30 with severe preeclampsia, admitted to the study center between June 2020 and January 2021.
Conditions
Preeclampsia
Setting
Single study center (hospital admissions); location not stated in the record
Planned enrollment (registry)
Not reported
Enrolled
90
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety.

    Monitoring: Not applicable; no compound was administered.

    The authors concluded (paraphrased): The authors found no significant relationship between serum MOTS-c and preeclampsia. They call for larger studies to clarify whether MOTS-c could be a biomarker or therapeutic target in preeclampsia.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • inappropriate endpoint: The study measures endogenous MOTS-c levels only. It gives no information on effects of administering MOTS-c.
    • small or imprecise: Only 30 patients per group, and the authors themselves state that large-scale research is needed.
    • abstract only: Only the abstract is available in the record. Methods, funding and conflicts are not reported.
    • confounding: Groups differed in smoking and other characteristics, and no adjustment for confounders is reported in the abstract.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 39469962, abstract (Conclusions, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 39469962, abstract (Material and methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 39469962, abstract (Conclusions, sentence 2) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 39469962, abstract (Material and methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 39469962, abstract (Material and methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).